Paving the way for immunotherapy in pediatric acute myeloid leukemia
| Autor: | Inge van der Werf, Gertjan J.L. Kaspers, Olaf Heidenreich, Friso G. Calkoen, Christian M. Zwaan, Stefan Nierkens, Joost B. Koedijk |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty immune monitoring medicine.medical_treatment Review acute myeloid leukemia immune landscape Immune profiling Immune system Antigen children SDG 3 - Good Health and Well-being medicine Intensive care medicine RC254-282 tumor immune microenvironment business.industry immune profiling Pediatric acute myeloid leukemia Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immunotherapy medicine.disease Clinical trial medicine.anatomical_structure Oncology Bone marrow immunotherapy business |
| Zdroj: | Cancers, Vol 13, Iss 4364, p 4364 (2021) Koedijk, J B, van der Werf, I, Calkoen, F G, Nierkens, S, Kaspers, G J L, Zwaan, C M & Heidenreich, O 2021, ' Paving the way for immunotherapy in pediatric acute myeloid leukemia : Current knowledge and the way forward ', Cancers, vol. 13, no. 17, 4364 . https://doi.org/10.3390/cancers13174364 Cancers |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13174364 |
| Popis: | Simple Summary Immunotherapy may be an attractive treatment option to increase survival, and to reduce treatment-related side effects, for children with acute myeloid leukemia (AML). While immunotherapies have shown successes in many cancer types, the development and subsequent clinical implementation have proven difficult in pediatric AML. To expedite the development of immunotherapy, it will be crucial to understand which pediatric AML patients are likely to respond to immunotherapies. Emerging research in solid malignancies has shown that the number and phenotype of immune cells in the tumor microenvironment is predictive of response to several types of immunotherapies. Such a predictive model may also be applicable for AML and, thus, knowledge on the immune cells infiltrating the bone marrow environment is needed. Here, we discuss the current state of knowledge on these infiltrating immune cells in pediatric AML, as well as ongoing immunotherapy trials, and provide suggestions concerning the way forward. Abstract Immunotherapeutic agents may be an attractive option to further improve outcomes and to reduce treatment-related toxicity for pediatric AML. While improvements in outcome have been observed with immunotherapy in many cancer types, immunotherapy development and implementation into patient care for both adult and pediatric AML has been hampered by an incomplete understanding of the bone marrow environment and a paucity of tumor-specific antigens. Since only a minority of patients respond in most immunotherapy trials across different cancer types, it will be crucial to understand which children with AML are likely to respond to or may benefit from immunotherapies. Immune cell profiling efforts hold promise to answer this question, as illustrated by the development of predictive scores in solid cancers. Such information on the number and phenotype of immune cells during current treatment regimens will be pivotal to generate hypotheses on how and when to intervene with immunotherapy in pediatric AML. In this review, we discuss the current understanding of the number and phenotype of immune cells in the bone marrow in pediatric AML, ongoing immunotherapy trials and how comprehensive immune profiling efforts may pave the way for successful clinical trials (and, ultimately, implementation into patient care). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|